semaglutide diuretic Wegovy may reduce need for diuretics for heart failure patients semaglutide #heartfailure2024 #hfa_esc | European
Description
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.
And for most UK patients, NHS access is realistically four years away, if eligibility criteria allow it at all
Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis
